Morgan Stanley analyst Michael Infante downgraded Enfusion (ENFN) to Equal Weight from Overweight with a price target of $11.25, up from $11. With Clearwater Analytics’ (CWAN) proposed acquisition of Enfusion at $11.25 per share, strategic value has been unlocked in Enfusion shares, the analyst tells investors in a research note. The firm says the acquisition accelerates shareholder value realization and renders historical issues obsolete.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENFN:
- BofA moves to No Rating on Enfusion after Clearwater Analytics deal
- Clearwater-Enfusion merger makes sense strategically, says Oppenheimer
- Enfusion downgraded to Market Perform from Outperform at William Blair
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Enfusion downgraded to Hold from Buy at Stifel